There is limited information about the overdose profile and LD50 of durvalumab. In case of overdose, the patient should be closely monitored for drug-related adverse events, and appropriate symptomatic treatment should be immediately initiated.L12627 Based on the findings of clinical studies, durvalumab had a risk of causing immune-mediated reactions, such as pneumonitis, hepatitis, and other serious infections. In animal reproductive studies, durvalumab caused fetal harm and this fetal toxicity may be possible in humans.L12621
Durvalumab is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment.A192789 Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,L12621 durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.L12621,L12627
Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 A192807 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma.L12621 In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ? 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy.A192789,L12627 On March 27, 2020, durvalumab was approved by the FDA for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).L12624
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Durvalumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Durvalumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Durvalumab. |
| Estrone | Estrone may increase the thrombogenic activities of Durvalumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Durvalumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Durvalumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Durvalumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Durvalumab. |
| Estriol | Estriol may increase the thrombogenic activities of Durvalumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Durvalumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Durvalumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Durvalumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Durvalumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Durvalumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Durvalumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Durvalumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Durvalumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Durvalumab. |
| Equol | Equol may increase the thrombogenic activities of Durvalumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Durvalumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Durvalumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Durvalumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Durvalumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Durvalumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Durvalumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Durvalumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Durvalumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Durvalumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Durvalumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Durvalumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Durvalumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Durvalumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Durvalumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Durvalumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Durvalumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Durvalumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Durvalumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Durvalumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Durvalumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Durvalumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Durvalumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Durvalumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Durvalumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Durvalumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Durvalumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Durvalumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Durvalumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Durvalumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Durvalumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Durvalumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Durvalumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Durvalumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Durvalumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Durvalumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Durvalumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Durvalumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Durvalumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Durvalumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Durvalumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Durvalumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Durvalumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Durvalumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Durvalumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Durvalumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Durvalumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Durvalumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Durvalumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Durvalumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Durvalumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Durvalumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Durvalumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Durvalumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Durvalumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Durvalumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Durvalumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Durvalumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Durvalumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Durvalumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Durvalumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Durvalumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Durvalumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Durvalumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Durvalumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Durvalumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Durvalumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Durvalumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Durvalumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Durvalumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Durvalumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Durvalumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Durvalumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Durvalumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Durvalumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Durvalumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Durvalumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Durvalumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Durvalumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Durvalumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Durvalumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Durvalumab. |